O-(4-iodobenzyl)hydroxyphthalimide | 1446092-99-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: O-(4-iodobenzyl)hydroxyphthalimide
• 英文别名: 2-((4-iodobenzyl)oxy)isoindoline-1,3-dione
• CAS: 1446092-99-4
• 化学式: C₁₅H₁₀INO₃
• 分子量: 379.154
• InChiKey: FIEDQVDKXZOUAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.02
• 重原子数：
  20.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  46.61
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  O-(4-iodobenzyl)hydroxyphthalimide 在 盐酸 、 一水合肼 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 为溶剂， 反应 4.5h， 生成 O-(4-iodobenzyl)hydroxylamine hydrochloride
  参考文献：
  名称：

  4-Alkyloxyimino-cytosine nucleotides: tethering approaches to molecular probes for the P2Y6 receptor

  摘要：

  4-烷氧亚氨基嘧啶核苷酸衍生物作为某些G蛋白偶联P2Y受体（P2YRs）的激动剂显示出高度效力。为了对P2Y6R激动剂进行荧光标记，我们在两个位置（胞苷衍生物的N4位和γ-磷酸基团）上探查了包括炔烃在内的各种功能团，用于点击化学反应。在CDP的嘧啶核碱4位上进行扩展亚氨基取代，相比于CTP衍生物中的γ-磷酸酯形成，通常更好地保持了P2Y6R的效力。荧光染料Alexa Fluor 488的共轭物16激活了在1321N1人星形胶质瘤细胞中表达的人P2Y6R，其EC50为9 nM，并且对这种受体的选择性远高于其他由尿嘧啶核苷酸激活的P2Y受体。流式细胞术检测到16对表达P2Y6R的细胞有特异性标记，而对野生型1321N1细胞无标记。此外，共聚焦显微镜显示16被内化（半衰期18分钟）并有表面结合的荧光。已知的P2Y6R配体抑制标记。16与P2Y6R的同源模型的理论对接预测了荧光团与TM3的外部部分之间的静电相互作用。因此，我们确定了N4-苄氧基团作为合成功能化类似物的结构容许位点，从而得到用于研究P2Y6R的高亲和力分子探针。

  DOI：

  10.1039/c3md00132f
• 作为产物：
  描述：

  N-羟基邻苯二甲酰亚胺 、 4-碘甲苯 在 叔丁基过氧化氢 、 四丁基碘化铵 作用下， 以 乙醚 、 癸烷 为溶剂， 反应 0.5h， 以81%的产率得到O-(4-iodobenzyl)hydroxyphthalimide
  参考文献：
  名称：

  Ultrasound accelerated synthesis of O-alkylated hydroximides under solvent- and metal-free conditions

  摘要：

  描述了一种新颖、可持续、环保、无溶剂和无金属催化剂的方法，用于NHPI和苄基/醚化合物之间的CDC反应。

  DOI：

  10.1039/c9ob02245g

文献信息

• NOVEL VASCULAR LEAKAGEAGE INHIBITOR
  申请人：Industry-Academic Cooperation Foundation, Yonsei University

  公开号：US20140378399A1

  公开（公告）日：2014-12-25

  The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present invention inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, and enhances the cortical actin ring structure, thereby inhibiting vascular leakage. Accordingly, the vascular leakage inhibitor of the present invention can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present invention is synthesized from commercially available or easily synthesizable pregnenolones, it has remarkably superior feasibility of commercial synthesis.

  本公开涉及一种新型血管渗漏抑制剂。本发明的新型血管渗漏抑制剂抑制血管内皮细胞凋亡，抑制由VEGF诱导的肌动蛋白应激纤维的形成，并增强皮质肌动蛋白环结构，从而抑制血管渗漏。因此，本发明的血管渗漏抑制剂可以预防或治疗由血管渗漏引起的各种疾病。由于本发明的血管渗漏抑制剂是由商业可获得或易于合成的孕酮合成的，因此具有明显优越的商业合成可行性。
• Electrochemical PINOylation of Methylarenes: Improving the Scope and Utility of Benzylic Oxidation through Mediated Electrolysis
  作者：Md Asmaul Hoque、Jack Twilton、Jieru Zhu、Matthew D. Graaf、Kaid C. Harper、Emilian Tuca、Gino A. DiLabio、Shannon S. Stahl

  DOI：10.1021/jacs.2c05974

  日期：2022.8.24

  A mediated electrosynthetic method has been developed for selective benzylic oxidation of methylarenes. Phthalimide-N-oxyl (PINO) radical generated by proton-coupled electrochemical oxidation of N-hydroxypthalimide serves as a hydrogen atom-transfer (HAT) mediator and as a radical trap for the benzylic radicals generated in situ. This mediated electrolysis method operates at much lower anode potentials

  已经开发了一种介导的电合成方法用于甲基芳烃的选择性苄基氧化。N-羟基邻苯二甲酰亚胺的质子耦合电化学氧化产生的邻苯二甲酰亚胺-N-氧基（PINO）自由基作为氢原子转移（HAT）介体和原位产生的苄基自由基的自由基陷阱。相对于单电子转移（SET）引发的苄基氧化的直接电解方法，这种介导的电解方法在低得多的阳极电位下运行。将 SET 和介导的 HAT 电解方法与一组常见底物进行直接比较表明，HAT 反应表现出显着改善的底物范围和官能团兼容性。PINOylated产物在光化学条件下很容易转化为相应的苯甲醇或苯甲醛衍生物，并且非甾体抗炎药塞来昔布的后期功能化凸显了该方法的合成实用性。
• O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1
  作者：William P. Malachowski、Maria Winters、James B. DuHadaway、Ariel Lewis-Ballester、Shorouk Badir、Jenny Wai、Maisha Rahman、Eesha Sheikh、Judith M. LaLonde、Syun-Ru Yeh、George C. Prendergast、Alexander J. Muller

  DOI：10.1016/j.ejmech.2015.12.028

  日期：2016.1

  Indoleamine 2,3-dioxygenase-1 (IDO1) is a promising therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathological immune suppression. Recently important advances have been made in understanding IDO1's catalytic mechanism. Although much remains to be discovered, there is strong evidence that the mechanism proceeds through a heme-iron bound alkylperoxy transition or intermediate state. Accordingly, we explored stable structural mimics of the alkylperoxy species and provide evidence that such structures do mimic the alkylperoxy transition or intermediate state. We discovered that O-benzylhydroxylamine, a commercially available compound, is a. potent sub-micromolar inhibitor of IDO1. Structure activity studies of over forty derivatives of O-benzylhydroxylamine led to further improvement in inhibitor potency, particularly with the addition of halogen atoms to the meta position of the aromatic ring. The most potent derivatives and the lead, O-benzylhydroxylamine, have high ligand efficiency values, which are considered an important criterion for successful drug development. Notably, two of the most potent compounds demonstrated nanomolar-level cell-based potency and limited toxicity. The combination of the simplicity of the structures of these compounds and their excellent cellular activity makes them quite attractive for biological exploration of IDO1 function and antitumor therapeutic applications. (C) 2015 Elsevier Masson SAS. All rights reserved.